ADCETRIS is being evaluated in: 1. A phase III clinical trial (the AETHERA trial) for patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT) 2. A phase II trial for relapsed or refractory CD30-positive non-Hodgkin lymphomas 3. A phase II trial for CD30-positive non-lymphoma malignancies 4. A phase II retreatment trial for relapsed patients who previously responded to ADCETRIS 5. A phase I trial in combination with multi-agent chemotherapy for front-line treatment of Hodgkin lymphoma 6. A phase I trial in combination with multi-agent chemotherapy for front-line treatment of mature T-cell lymphomas. 7.A trial in CD30-positive cutaneous T-cell lymphomas to begin in mid-2012 8. A front-line trial in Hodgkin lymphoma to begin by late 2012 or early 2013 9. A front-line trial in mature T-cell lymphomas. to begin by late 2012 or early 2013
And today the pps gave up much of the $1+ it gained on Monday. Not surprising given that there really wasn't a good reason for the jump and that today was a bad day overall, but there seemed to be above-average volume today as well.
The giant short position for this company with a very good product and a good technology platform does not make any sense. Any buyout offer above the current price would send the stock price into the heavens. An excellent fit would be BMY which has dozens of antibodies from the Medarex acquision.